Neutropenic Fever-Reference-Cited by-同舟云学术

Neutropenic Fever

Published:2024 Issue: Volume: Page:303-309
ISSN:
Container-title:The EBMT Handbook
language:en
Short-container-title:

Author:

Mikulska Malgorzata

Abstract

AbstractFever during neutropenia is almost universal after an HCT. In neutropenic HCT recipients, clinicians are faced with a unique combination of issues: (1) high incidence of bacterial bloodstream infections, (2) high mortality in case of infections due to Gram-negative bacteria unless effective antibiotic treatment is provided promptly, and (3) numerous causes of fever other than bacterial infection.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-031-44080-9_35

Reference17 articles.

1. Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4:e573–83.

2. Averbuch D, Orasch C, Cordonnier C. ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98:1826–35.

3. Averbuch D, Tridello G, Hoek J, et al. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017;65(11):1819–28.

4. Beyar-Katz O, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2017;6:CD003914.

5. de Jonge NA, Sikkens JJ, Zweegman S, et al. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Lancet Haematol. 2022;9(8):e563–72.